244 related articles for article (PubMed ID: 26892980)
1. Genetic variation frequencies in Wilms' tumor: A meta-analysis and systematic review.
Deng C; Dai R; Li X; Liu F
Cancer Sci; 2016 May; 107(5):690-9. PubMed ID: 26892980
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
3. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
4. Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis.
Bu Q; He H; Fan D; Lyu J; Pan Z; You H
Pathol Res Pract; 2018 Nov; 214(11):1772-1777. PubMed ID: 30143352
[TBL] [Abstract][Full Text] [Related]
5. Genetics of Wilms' tumor.
Coppes MJ; Egeler RM
Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
[TBL] [Abstract][Full Text] [Related]
6. A third Wilms' tumor locus on chromosome 16q.
Maw MA; Grundy PE; Millow LJ; Eccles MR; Dunn RS; Smith PJ; Feinberg AP; Law DJ; Paterson MC; Telzerow PE
Cancer Res; 1992 Jun; 52(11):3094-8. PubMed ID: 1317258
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
8. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors.
Perotti D; Gamba B; Sardella M; Spreafico F; Terenziani M; Collini P; Pession A; Nantron M; Fossati-Bellani F; Radice P
Oncogene; 2008 Jul; 27(33):4625-32. PubMed ID: 18391980
[TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
10. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor.
Huff V; Reeve AE; Leppert M; Strong LC; Douglass EC; Geiser CF; Li FP; Meadows A; Callen DF; Lenoir G
Cancer Res; 1992 Nov; 52(21):6117-20. PubMed ID: 1356625
[TBL] [Abstract][Full Text] [Related]
11. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
12. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
13. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
14. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
15. Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome.
Haruta M; Arai Y; Okita H; Tanaka Y; Takimoto T; Sugino RP; Yamada Y; Kamijo T; Oue T; Fukuzawa M; Koshinaga T; Kaneko Y
Neoplasia; 2019 Jan; 21(1):117-131. PubMed ID: 30530054
[TBL] [Abstract][Full Text] [Related]
16. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
18. [Molecular genetics of Wilms' tumor].
Papezová M; Mares J; Goetz P
Cas Lek Cesk; 2001 Jun; 140(11):323-7. PubMed ID: 11431850
[TBL] [Abstract][Full Text] [Related]
19. Constitutional and somatic mutations in the WT1 gene in Wilms' tumor patients.
Nordenskjöld A; Friedman E; Sandstedt B; Söderhäll S; Anvret M
Int J Cancer; 1995 Nov; 63(4):516-22. PubMed ID: 7591260
[TBL] [Abstract][Full Text] [Related]
20. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]